Oncotarget

Clinical Research Papers:

This article has been corrected. Correction in: Oncotarget. 2018; 9:15435.

Efficacy of transcatheter arterial chemoembolization for liver metastases arising from pancreatic cancer

Jun-Hui Sun _, Tan-Yang Zhou, Yue-Lin Zhang, Guan-Hui Zhou, Chun-Hui Nie, Tong-Yin Zhu, Sheng-Qun Chen, Bao-Quan Wang, Song Ye, Yan Shen, Hua Guo, Wei-Lin Wang and Shu-Sen Zheng

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:39746-39755. https://doi.org/10.18632/oncotarget.14642

Metrics: PDF 1308 views  |   HTML 1694 views  |   ?  


Abstract

Jun-Hui Sun1,2,3,4, Tan-Yang Zhou1,2,3,4, Yue-Lin Zhang1,2,3,4, Guan-Hui Zhou1,2,3,4, Chun-Hui Nie1,2,3,4, Tong-Yin Zhu1,2,3,4, Sheng-Qun Chen1,2,3,4, Bao-Quan Wang1,2,3,4, Song Ye1,2,3,4, Yan Shen1,2,3,4, Hua Guo1,2,3,4, Wei-Lin Wang1,2,3,4 and Shu-Sen Zheng1,2,3,4

1 Hepatobiliary and Pancreatic Interventional Treatment Center, Division of Hepatobiliary and Pancreatic Surgery, China

2 Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, China

3 Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, Zhejiang, Hangzhou, China

4 Collaborative Innovation Center for Diagnosis Treatment of Infectious Diseases, Zhejiang University, Hangzhou, Zhejiang, China

Correspondence to:

Jun-Hui Sun, email:

Wei-Lin Wang, email:

Shu-Sen Zheng, email:

Keywords: pancreatic tumor, hepatic metastasis, TACE, intervention, efficacy

Received: August 21, 2016 Accepted: December 27, 2016 Published: January 13, 2017

Abstract

Purpose: The aim of the study was to evaluate the efficacy of transcatheter arterial chemoembolization (TACE) in treating patients with liver metastases from pancreatic cancer, and explore the prognostic risk factors.

Results: Three of the 27 patients were totally recovered, and 12 were partially alleviated. The total efficacy rate was 55.6% (15/27). The median survival time was 13.6 months, and the 0.5-, 1-, 2-, 3-, and 5-year survival rates were 70.4% (19/27), 48.1% (13/27), 22.2% (6/27), 14.8 (4/27), 11.1% (3/27), respectively. None of the groups showed any severe complications. Univariate analysis showed that pathological type, concomitant therapies for liver metastasis, vascular supply, CA199 levels and extrahepatic metastasis were related to prognosis (P < 0.05). Multivariate analysis indicated that pancreatic cancer pathology and extrahepatic metastasis were independent risk factors influencing patients’ prognosis (χ2 = 13.182, 17.989, P < 0.05).

Methods: The clinical records of 27 patients with lliver metastases from pancreatic cancer diagnosed at the First Affiliated Hospital of Zhejiang University between May 2009 and May 2015 were retrospectively analyzed. The short-term and long-term efficacy and toxic side effects of TACE were observed. The prognostic risk factors were analyzed using Cox (proportional hazards) regression model.

Conclusion: TACE is an effective therapy for treating liver metastases from pancreatic malignancy. Pathological type and extrahepatic metastasis of pancreatic tumor are independent risk factors for patients’ prognosis. The prognosis of patients with liver metastasis from pancreatic neuroendocrine neoplasm is superior to that of extrahepatic metastasis.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 14642